Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28254695 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2ALDH1A1RAB9AHPGD | |
| SCHEMBL535803 | 0.84 | LMNA (0.50) | LMNASMN1; SMN2ALDH1A1RAB9AHPGD | |
| SCHEMBL1425231 | 0.84 | LMNA (0.52) | LMNASMN1; SMN2ALDH1A1RAB9AHPGD | |
| SCHEMBL28950323 | 0.81 | LMNA (0.47) | LMNASMN1; SMN2ALDH1A1RAB9AHPGD | |
| SCHEMBL5162822 | 0.80 | EHMT2 (0.50) | LMNASMN1; SMN2ALDH1A1RAB9AHPGD | |
| SCHEMBL670302 | 0.79 | ALDH1A1 (0.50) | LMNASMN1; SMN2ALDH1A1RAB9AHPGD | |
| SCHEMBL10347772 | 0.77 | EHMT2 (0.47) | LMNASMN1; SMN2ALDH1A1RAB9AHPGD | |
| Propionic Acid SCHEMBL28700286 | 0.74 | EHMT2 (0.63) | LMNASMN1; SMN2ALDH1A1RAB9AHPGD | |
| SCHEMBL1607377 | 0.74 | LMNA (0.51) | LMNASMN1; SMN2ALDH1A1RAB9AHPGD | |
| SCHEMBL2738375 | 0.73 | LMNA (0.51) | LMNASMN1; SMN2ALDH1A1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140017797-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | De Staadt der Nederlanden, vert doorde minister van VWS (NL) | 2014-01-16 | — | — | US | claimed |
| EP-2651961-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | De Staat Der Nederlanden, Vert. Door De Minister Van VWS (NL) | 2013-10-23 | — | — | EP | claimed |
| WO-2012081978-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2012-06-21 | — | — | WO | claimed |
| US-20250092092-A1 | ANTIBODY/DRUG CONJUGATES AND METHODS OF USE | A28 THERAPEUTICS INC. | 2025-03-20 | — | — | US | disclosed |
| EP-2874663-B1 | NANOCONSTRUCTS WITH PHARMACOLOGICAL ACTIVITY | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2018-01-10 | — | — | EP | disclosed |
| US-20150224061-A1 | NANOCONSTRUCTS WITH PHARMACOLOGICAL ACTIVITY | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2015-08-13 | — | — | US | disclosed |
| EP-2874663-A1 | NANOCONSTRUCTS WITH PHARMACOLOGICAL ACTIVITY | Università Degli Studi Di Milano - Bicocca (IT) | 2015-05-27 | — | — | EP | disclosed |
| US-20140363491-A1 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO., LTD. (JP) | 2014-12-11 | — | — | US | disclosed |
| EP-1863448-B1 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-8758810-B2 | Liposome compositions | MEBIOPHARM CO., LTD. (JP) | 2014-06-24 | — | — | US | disclosed |
| WO-2014013473-A1 | NANOCONSTRUCTS WITH PHARMACOLOGICAL ACTIVITY | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2014-01-23 | — | — | WO | disclosed |
| US-20140017797-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | De Staadt der Nederlanden, vert doorde minister van VWS (NL) | 2014-01-16 | — | — | US | disclosed |
| EP-2651961-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | De Staat Der Nederlanden, Vert. Door De Minister Van VWS (NL) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012081978-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2012-06-21 | — | — | WO | disclosed |
| US-20110081404-A1 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO., LTD. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-7829113-B2 | comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment | MEBIOPHARM CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| WO-2008030818-A2 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO., LTD. (US) | 2008-03-13 | — | — | WO | disclosed |
| EP-1863448-A2 | NOVEL LIPOSOME COMPOSITIONS | Mebiopharm Co., Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20060222696-A1 | comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment | MEBIOPHARM CO., LTD. (JP) | 2006-10-05 | — | — | US | disclosed |
| WO-2006099169-A2 | NOVEL LIPOSOME COMPOSITIONS | MEBIOPHARM CO., LTD. (JP) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060222696-A1 | comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment | PHOSPHO1, SGMS2, SGMS1 | LMNA 647/4885SMN1; SMN2 3865/4885ALDH1A1 3056/4885 |
| US-20140017797-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | PTMS, ALPG, TPX2 | LMNA 4464/4885SMN1; SMN2 4831/4885ALDH1A1 4863/4885 |
| US-20250092092-A1 | ANTIBODY/DRUG CONJUGATES AND METHODS OF USE | CD44, FCGR2A, FCGR1A | LMNA 3132/4885SMN1; SMN2 2859/4885ALDH1A1 684/4885 |
| US-20140363491-A1 | NOVEL LIPOSOME COMPOSITIONS | PHOSPHO1, LIPA, LYPLAL1 | LMNA 1324/4885SMN1; SMN2 3194/4885ALDH1A1 4667/4885 |
| US-20110081404-A1 | NOVEL LIPOSOME COMPOSITIONS | PHOSPHO1, LIPA, LYPLAL1 | LMNA 1324/4885SMN1; SMN2 3194/4885ALDH1A1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.